Corium International,Inc. (NASDAQ:CORI) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Corium International,Inc. (NASDAQ:CORI) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition.

On August 3, 2017, Corium International, Inc. (the “Company”) issued a press release to announce its financial results for its second quarter ended June 30, 2017.A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information furnished with this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02.Financial Statements and Exhibits.

(d)Exhibits.

Exhibit Number

Description

99.1

Press release dated August 3, 2017.


Corium International, Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 cori_Ex99_1 Exhibit 99.1   FOR IMMEDIATE RELEASE   Corium Reports Recent Corporate Highlights and Financial Results for Third Quarter Fiscal 2017   MENLO PARK,…
To view the full exhibit click here

About Corium International,Inc. (NASDAQ:CORI)

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.